Results 211 to 220 of about 79,137 (303)

Predicting Recovery After Joint Bleeding in Persons With Bleeding Disorders

Haemophilia, Volume 32, Issue 3, Page 691-698, May/June 2026.
ABSTRACT Introduction Joint bleeds are burdensome and recovery differs from bleed to bleed. Identifying predictors of recovery could enable personalized treatment and monitoring; aiming to prevent long‐term joint deterioration, and facilitate faster return to activities. Aim To identify predictors of time to recovery after joint bleeding in people with
Gijs Aertssen, Lize F. D. van Vulpen, Wouter Foppen, Flora H. P. van Leeuwen, Merel A. Timmer   +4 more
wiley   +1 more source

von Willebrand disease combined with other hemostasis disorders: an overlooked clinical entity. [PDF]

Res Pract Thromb Haemost
Seidizadeh O, Mannucci PM, Peyvandi F.
europepmc   +1 more source

Inherited Bleeding Disorders in Pregnancy: Obstetric Management and Outcomes From a Tertiary Care Centre

Haemophilia, Volume 32, Issue 3, Page 801-808, May/June 2026.
ABSTRACT Objective This study aimed to evaluate the obstetric management, complications and clinical characteristics of pregnant women diagnosed with hereditary coagulation factor deficiencies at a tertiary obstetric centre over a 10‐year period. Methods We retrospectively reviewed a total of 19 pregnancies in 17 women with hereditary coagulation ...
Melis Altug Inan, Bilge Kapudere, Hanne Bulat Cim, Abdulkadir Turgut   +3 more
wiley   +1 more source

Ruptured Anterior Communicating Artery Aneurysm Associated with von Willebrand Disease Treated Using the Woven EndoBridge Device: An Illustrated Case. [PDF]

J Neuroendovasc Ther
Koike Y, Shindo K, Endo H, Ogino T, Nakamura H.   +4 more
europepmc   +1 more source

Modeling response to high-purity von Willebrand factor: toward tailored dosing during surgery in von Willebrand disease. [PDF]

Blood Adv
Daniel MY, Rauch A, Paris C, Jeanpierre E, Goudemand J, Marichez C, Pradines B, Zawadzki C, Dupont A, Denis CV, Lenting PJ, Susen S, Delavenne X.   +12 more
europepmc   +1 more source

Allele-selective disruption of pathogenic VWF variants in type 2 von Willebrand disease using CRISPR/Cas9. [PDF]

Blood Adv
Bär I, Groten SA, Barraclough A, Bürgisser PE, van Kwawegen C, Lenting PJ, van Moort I, Eikenboom JCJ, Leebeek FWG, Voorberg J, van den Biggelaar M, Bierings R.   +11 more
europepmc   +1 more source

Assessing the Impact of the 2021 VWD Guidelines on the Diagnosis/Management of Low VWF Patients

Haemophilia, Volume 32, Issue 3, Page 772-778, May/June 2026.
ABSTRACT Introduction The 2021 ASH/ISTH/NHF/WFH VWD diagnosis guidelines recommend Type 1 VWD diagnoses for patients with (a) VWF <0.30 IU/mL or (b) ‘Low VWF’ 0.30–0.50 IU/mL with the presence of abnormal bleeding. This recommendation recategorizes ‘Low VWF’ patients with abnormal bleeding into Type 1 VWD.
Michael Dong, Joanna Larson, Sepideh Saroukhani, Miguel Escobar, Lakshmi Srivaths   +4 more
wiley   +1 more source

Managing Anesthesia for a Patient With Von Willebrand Disease: A Case Report. [PDF]

Cureus
Singavarapu J, Borodulina G.
europepmc   +1 more source

Noninvasive Tests for Predicting Decompensation in Compensated Advanced Chronic Liver Disease: A Comprehensive Review

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Strong non‐invasive tests (NITs) are needed to predict decompensation in patients with compensated advanced chronic liver disease (cACLD) and improve personalized patient care. We conducted a comprehensive review of the studies evaluating the effectiveness of NITs in predicting decompensation or liver‐related death in patients with cACLD.
Audrey Payancé, Pierre‐Emmanuel Rautou, Jérôme Boursier, Laurent Castera, Dominique Valla, Laure Elkrief   +5 more
wiley   +1 more source

Conservative Management of Hemoperitoneum Due to a Ruptured Hemorrhagic Ovarian Cyst in Type 3 von Willebrand Disease. [PDF]

Cureus
Mahfoud H, Laaboudi R, Elkhorassani M, Elachhab N, Bargach S.   +4 more
europepmc   +1 more source